Price
Target price
€4.74
€4.74
-3.110%
-0.154
-3.110%
€8.60
12.03.26 / Tradegate
WKN: A3C4ZC / Symbol: XERS / Name: Xeris Biopharma / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Xeris Biopharma Holdings Inc. Stock
Xeris Biopharma Holdings Inc. took a tumble today and lost -€0.154 (-3.110%).
Xeris Biopharma Holdings Inc. is currently one of the favorites of our community with 9 Buy predictions and no Sell predictions.
With a target price of 8 € there is a hugely positive potential of 68.85% for Xeris Biopharma Holdings Inc. compared to the current price of 4.74 €.
Pros and Cons of Xeris Biopharma Holdings Inc. in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
M***** P*******
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xeris Biopharma Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc. | -3.110% | -9.060% | -21.880% | 14.500% | -24.972% | 271.550% | 17.861% |
| Heron Therapeutics Inc. | -0.180% | -14.915% | -16.119% | -62.443% | -25.494% | -59.033% | -94.132% |
| Evolus Inc | 0.000% | -4.938% | 26.230% | -61.176% | -15.229% | -40.387% | -52.982% |
| Sangamo Therapeutics Inc. | -1.270% | 6.769% | 8.607% | -62.221% | -0.800% | -83.774% | -96.399% |
Comments
Xeris Biopharma (XERS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Show more
Ratings data for XERS provided by MarketBeat
